Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714878 | 1.00 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL17847294 | 0.99 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL17847295 | 0.99 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL19714941 | 0.88 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2TSHRRECQL | |
| SCHEMBL19714942 | 0.88 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2TSHRRECQL | |
| SCHEMBL17847280 | 0.85 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL17847688 | 0.83 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2ADORA2AADORA3 | |
| SCHEMBL19714854 | 0.83 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2TSHRRECQL | |
| SCHEMBL19714855 | 0.83 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2TSHRRECQL | |
| SCHEMBL17847685 | 0.83 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233861-B1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL) PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2019-04-10 | — | — | EP | disclosed |
| US-10093675-B2 | 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2018-10-09 | — | — | US | disclosed |
| US-20170362236-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362236-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | PNP, UNG, NUDT1 | NPC1 3580/4885RAB9A 1999/4885SMN1; SMN2 3293/4885 |
| US-10093675-B2 | 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications | PNP, UNG, NUDT1 | NPC1 3580/4885RAB9A 1999/4885SMN1; SMN2 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.